Geron Announces Presentation at American Association for Cancer Research Annual Meeting
Abstract Title: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia (Abstract #1101)
|AACR Session Title:||Combination Therapy 1|
|Session Date:||Monday, April 3, 2017|
|Session Time:||8:00 a.m. ET - 12:00 p.m. ET|
In accordance with AACR policies, abstracts submitted to the AACR Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the AACR Annual Meeting, information contained in the abstract, as well as additional data and information to be presented at the Annual Meeting, may not be made public before the abstract has been presented in connection with the AACR Annual Meeting.
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 email@example.com firstname.lastname@example.org